Expedited Pathways Comparisons - US EU CHN

Published on: Oct 19, 2021

This presentation from Parexel's virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs" outlines regional comparisons of expedited pathways in US, EU and China.


Get Exclusive PDF Access

Return to Insights Center

Related Insights

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Blog

Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development

Jan 22, 2025

Webinar

Assessing appropriate use of ECAs in clinical trials

May 28, 2023

Playbook

Streamlining development in the EU: Strategies for smoother CTA submissions

Feb 27, 2025

Webinar

Accelerated Early Phase Decision-Making – Insider Insights to Speed Development

Jan 7, 2025

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Playbook

What emerging trends in the FDA’s most coveted designations might tell us

Feb 8, 2024

Related Insights

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Playbook

Early-phase development strategies for navigating regulatory complexity in the EU

Apr 29, 2024

Blog

Overcoming risks in Phase 3 trials to accelerate time to market

Jan 22, 2025

Article

Australia: The Regulatory and Reimbursement Environment

Aug 28, 2023

Show more